Literature DB >> 19232683

Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.

Roza Chaireti1, Cecilia Jennersjö, Tomas L Lindahl.   

Abstract

INTRODUCTION: The present study evaluated possible relations between various markers of thrombin generation, D-dimer and venous thromboembolism in outpatients with and without the FV Leiden and the protrombin mutations. PATIENTS AND METHODS: Our cohort consisted of 98 patients with the FV Leiden and 15 with the prothrombin mutation and an equal number of age- and gender-matched controls. All subjects were investigated due to suspicion of venous thromboembolism and the diagnosis was objectively confirmed or refuted.
RESULTS: We compared the D-dimer values and the thrombin generation markers among different patient groups (with/without thromboembolism, with/without genetic factors, gender-linked). The only statistically significant difference noted was prolonged time both for the initiation and termination of thrombin generation in patients with thrombosis. This applied to controls and to patients heterozygous for the FV Leiden. Additionally, the D-dimer values were elevated in patients with the FV Leiden. No difference was found among the patients with prothrombin mutation and their controls. DISCUSSION: Multi-variant analysis indicated that the difference in D-dimer between FV Leiden patients and controls was due to the greater number of patients with confirmed thrombosis in the former group, a finding supported by an independent prospective study on postoperative thrombosis. Neither D-dimer concentration nor thrombin generation depend on FV Leiden. The total amount of thrombin generated was not related to diagnosis. The prolonged thrombin generation noted in controls and FV Leiden heterozygotes with thrombosis may point out different thrombin generation profiles in different patient populations and requires further studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19232683     DOI: 10.1016/j.thromres.2008.12.033

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Factor V Leiden, prothrombin 20210G>A, MTHFR 677C>T and 1298A>C, and homocysteinemia in Tunisian blood donors.

Authors:  Samira Hadhri; Mohamed Ben Rejab; Hajer Guedria; Lamia Ifa; Noureddine Chatti; Hadef Skouri
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

Review 2.  Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future.

Authors:  Giuseppe Lippi; Gianfranco Cervellin; Massimo Franchini; Emmanuel J Favaloro
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

3.  Novel 2-aminobenzamides as potential orally active antithrombotic agents.

Authors:  Amit Verma; Rajani Giridhar; Ashish Kanhed; Anshuman Sinha; Pratik Modh; Mange R Yadav
Journal:  ACS Med Chem Lett       Date:  2012-10-31       Impact factor: 4.345

4.  Thrombin generation profile in non-thrombotic factor V Leiden carriers.

Authors:  Paul Billoir; Thomas Duflot; Marielle Fresel; Marie Hélène Chrétien; Virginie Barbay; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

5.  Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis.

Authors:  Daria Eppenberger; Henning Nilius; Betsy Anagnostelis; Carola A Huber; Michael Nagler
Journal:  Front Cardiovasc Med       Date:  2022-04-07

6.  Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics.

Authors:  Klas Boeer; Leonid Cuznetov; Wolfgang Loesche
Journal:  Thromb J       Date:  2013-11-12

7.  D-dimer, thrombin generation, and risk of a first venous thrombosis in the elderly.

Authors:  Huijie Wang; Frits R Rosendaal; Mary Cushman; Astrid van Hylckama Vlieg
Journal:  Res Pract Thromb Haemost       Date:  2021-06-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.